Navigation Links
Adeona's Planned Clinical Trial of Proprietary Zinc-Based Therapy in Lou Gehrig's Disease is Hot Topic at 2011 California ALS Research Summit
Date:9/30/2011

a wholly owned clinical reference laboratory that provides a broad array of chemistry and microbiology diagnostic tests. For more information, please visit Adeona's website at www.adeonapharma.com.

RILUTEK® (riluzole) is a registered trademark of sanofi-aventis U.S. LLC.

This release includes forward-looking statements on Adeona's current expectations and projections about future events. In some cases forward-looking statements can be identified by terminology such as "may," "could," "potential," "positions," "continue," "expects," "anticipates," "intends," "planned," "believe," "estimates," and similar expressions. These statements are based upon current beliefs, expectations and assumptions and are subject to a number of risks and uncertainties, many of which are difficult to predict and include statements regarding the potential role of zinc in the treatment of ALS and the belief that high doses of zinc can reduce toxicity. The forward-looking statements are subject to risks and uncertainties that could cause actual results to differ materially from those set forth or implied by any forward-looking statements. Important factors that could cause actual results to differ materially from those reflected in Adeona's forward-looking statements include, among others, our failure to obtain regulatory approval or market approval of drug candidates in the treatment of ALS, failure to obtain approval to conduct the planned trial, failure of the planned clinical trial to have favorable results such as a failure to show benefits of zinc therapy in ALS patients, a failure of the treatment group to have a decrease in toxicity from unbound glutamate, and other factors described in Adeona's report on Form 10-K for the year ended December 31, 2010 and any other filings with the SEC. The information in this release is provided only as of the date of this release, and Adeona undertakes no obligat
'/>"/>

SOURCE Adeona Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. Plavix(R) Indications Expanded in Japan to Include Patients with Acute Coronary Syndrome for Whom Percutaneous Coronary Intervention Is Being Planned
2. TargeGen Announces Planned Initiation of Clinical Trial of JAK2 Inhibitor TG101348 in Myeloproliferative Disease Patients, and Presentations at ASH
3. Encorium Announces the Initiation of a Strategic Partnership With Prologue Research After the Postponement of Negotiations Regarding Its Planned Acquisition; Strategic Reorganization and Cost Reduction Plan Initiated as Strategic Alternatives are Investig
4. Vical Receives Milestone Payment from Merck & Co., Inc. Triggered by Planned Initiation of Investigational Cancer DNA Vaccine Trial
5. Celtic Pharma Announces Update on Status of XERECEPT(R) Program Sale Planned in 2009
6. Hana Biosciences Announces Successful Planned Independent Safety Analysis Supports Ability to Complete Pivotal rALLy Clinical Trial of Marqibo, Its Lead Novel Anti-Cancer Compound
7. US FDA Approves Extavia(R) - the First in a New Portfolio of Planned MS Therapies from Novartis to Help Patients with this Devastating Disease
8. Anthera Pharmaceuticals Announces Agreement With the FDA on a SPA for Planned Phase 3 Varespladib A-002 Study; Daniel K. Spiegelman Joins Board of Directors
9. Xanodyne Announces Planned President & CEO Succession
10. Breast Cancer Patient First in Latin America to Receive Treatment Using Elekta VMAT Planned with Monaco Software
11. Phase 3 Trial of Aflibercept in Second-Line Metastatic Colorectal Cancer to Continue as Planned at Recommendation of Independent Data Monitoring Committee
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/30/2014)... 2014 Cynosure, Inc. (NASDAQ: ... for non-invasive and minimally invasive applications, today announced that the ... Officer and Chief Financial Officer Timothy W. Baker ... 53, will continue to serve as CFO and will take ... remains Chairman and Chief Executive Officer. "Tim ...
(Date:7/30/2014)... -- Packaging Coordinators, Inc. (PCI) is pleased to announce it ... Services Limited (Penn Pharma). Penn Pharma is headquartered in Tredegar, ... United Kingdom and operates regional offices in ... Tokyo , Japan. Penn Pharma offers both drug ... form manufacturing, as well as Clinical Packaging, Labeling, and ...
(Date:7/30/2014)... MIAMI , July 30, 2014   Medical ... they have been awarded a Department of Defense (US ... months to supply a mobile MRI diagnostic machine and ... Small Business (WOSB) through the Small Business Administration (SBA), ... in the field with the latest medical diagnostic equipment. ...
Breaking Medicine Technology:Cynosure Appoints Chief Operating Officer and Chief Financial Officer Timothy W. Baker as President 2PCI Announces Definitive Agreement to Acquire Penn Pharma 2PCI Announces Definitive Agreement to Acquire Penn Pharma 3PCI Announces Definitive Agreement to Acquire Penn Pharma 4PCI Announces Definitive Agreement to Acquire Penn Pharma 5Medical Equipment Solutions Corp. Awarded $2 Million contract To Service DoD 2
... Inc. today announced publication of results from a pivotal ... the treatment of breakthrough cancer pain (BTCP). The article, ... Pectin Nasal Spray (FPNS) in the treatment of breakthrough ... the peer-reviewed journal from the International Association for the ...
... October 4, 2010 ... ... var shortURL ... longUrl, so we need to grab the first one. for (var r in data.results) { first_result = ...
Cached Medicine Technology:Archimedes Pharma Announces Publication of a Pivotal Clinical Study of Fentanyl Pectin Nasal Spray (FPNS) in Pain, the Peer-Reviewed Journal from the International Association for the Study of Pain 2Archimedes Pharma Announces Publication of a Pivotal Clinical Study of Fentanyl Pectin Nasal Spray (FPNS) in Pain, the Peer-Reviewed Journal from the International Association for the Study of Pain 335th ESMO Congress: Milan, Italy (FieraMilanoCity), 8-12 October 2010 - Press Programme Curtain Raiser 235th ESMO Congress: Milan, Italy (FieraMilanoCity), 8-12 October 2010 - Press Programme Curtain Raiser 335th ESMO Congress: Milan, Italy (FieraMilanoCity), 8-12 October 2010 - Press Programme Curtain Raiser 435th ESMO Congress: Milan, Italy (FieraMilanoCity), 8-12 October 2010 - Press Programme Curtain Raiser 535th ESMO Congress: Milan, Italy (FieraMilanoCity), 8-12 October 2010 - Press Programme Curtain Raiser 635th ESMO Congress: Milan, Italy (FieraMilanoCity), 8-12 October 2010 - Press Programme Curtain Raiser 735th ESMO Congress: Milan, Italy (FieraMilanoCity), 8-12 October 2010 - Press Programme Curtain Raiser 835th ESMO Congress: Milan, Italy (FieraMilanoCity), 8-12 October 2010 - Press Programme Curtain Raiser 935th ESMO Congress: Milan, Italy (FieraMilanoCity), 8-12 October 2010 - Press Programme Curtain Raiser 1035th ESMO Congress: Milan, Italy (FieraMilanoCity), 8-12 October 2010 - Press Programme Curtain Raiser 1135th ESMO Congress: Milan, Italy (FieraMilanoCity), 8-12 October 2010 - Press Programme Curtain Raiser 12
(Date:7/30/2014)... The Dr. Hector P. Garcia Memorial Foundation, ... proposed naming of the new primary care facility in ... Health Center. , The proposed 40,000 sq. ft. facility ... chronic disease management programs, pharmacy services and wellness and ... home model center. , Dr. Hector P. Garcia, for ...
(Date:7/30/2014)... July 30, 2014 Decene is ... a chain of ten carbon atoms with one ... typical of 1-decenes. It can be used as ... intermediate to produce epoxides, amines, oxo alcohols, synthetic ... , Early buyers will receive 10% customization on ...
(Date:7/30/2014)... -- Medical costs for chronic obstructive pulmonary disease (COPD) ... each year, according to new research from the U.S. ... financial toll of COPD (which includes emphysema and chronic ... by 2020. "For the first time, our analyses ... health practitioners with estimates of the economic burden of ...
(Date:7/30/2014)... (PRWEB) July 30, 2014 The global digital ... 2013 and is expected to grow at a CAGR of ... The demand for digital pathology is growing and is expected ... The use of scanners and image analysis software enable pathologists ... for patients. , In 2013, the North American market was ...
(Date:7/30/2014)... Los Angeles, CA (July 30, 2014) With the ... has become a popular science and researchers must ... in the study of stroke rehabilitation. A new ... discusses a systematic shift in perspective and suggests ... brain would strongly promote stroke motor recovery, for ...
Breaking Medicine News(10 mins):Health News:Dr. Hector P Garcia Memorial Foundation Supports New Health Care Facility 2Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 2Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 3Health News:Europe 1-decene Market is Expected to Reach 251.7 thousand MT in 2018 - New Report by MicroMarket Monitor 4Health News:Annual COPD Costs To Hit $49 Billion by 2020: CDC 2Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 2Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 3Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 4Health News:Global Digital Pathology Market To See 11.8% CAGR to 2018 Says a New Research Report Available at ReportsnReports.com 5Health News:Neuro researchers advocate for a shift in thinking for stroke rehabilitation 2
... Rare Diseases, BETHESDA, Md., April 24 ... of Representatives for passing,legislation to reauthorize the Small ... testimony from Robert J. Beall, Ph.D., president and ... requiring that,special attention be given to research for ...
... The following are,excerpts from an article in The ... Republican National Committee:, Congressional Democrats are backing away ... saying that even if,their party controls the White House ... some senators, the promises made by Sens. Barack Obama ...
... (Nasdaq: ONXX ) today announced that it ... Conference on Thursday,May 1, at 8:00 a.m. Eastern ... of the presentation on our website at:, ... listeners log on 15 minutes early in order ...
... how brain cell communication may be altered in schizophrenia ... at the Medical College of Georgia, a 2008 Distinguished ... Alliance Eminent Scholar in Neuroscience and professor in the ... of 11 scientists to receive the award, which includes ...
... Perrigo Company,(Nasdaq: PRGO ; TASE) today announced that ... Administration (FDA) to market over-the-counter (OTC),Nicotine Polacrilex Gum USP, ... The FDA has determined the product to be ... mg (base) and 4 mg,(base), which is an aid ...
... April 24 Karen Ignagni,President and CEO ... issued,the following statement commending the Senate on ... Senate:, (Logo: http://www.newscom.com/cgi-bin/prnh/20040830/AHIPLOGO ), ... the basis of their genetic,makeup. We applaud ...
Cached Medicine News:Health News:Cystic Fibrosis Foundation Lauds Congress for Passage of Small Business Innovation Research Program 2Health News:RNC: Dems Hedge on Healthcare 2Health News:Dr. Mei honored by mental health research charity for schizophrenia studies 2Health News:Dr. Mei honored by mental health research charity for schizophrenia studies 3Health News:Perrigo Receives FDA Approval to Market Orange, Coated Nicotine Gum 2
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
Medicine Products: